IMVT Share Price Performance
US$28.96
15.04 (108.05%)
29.6% undervalued intrinsic discount
US$41.13
Fair Value
Price US$28.96
AnalystConsensusTarget US$41.13
AnalystHighTarget US$57.00
AnalystLowTarget US$22.00
Fair ValueUS$41.13
Share Pricen/a
Immunovant, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
IMVT Community Narratives
AN
Fair Value
·Fair Value US$41.13 29.6% undervalued intrinsic discount
FcRn Autoimmune Treatments Will Build Durable Long Term Potential For This Undervalued Biotech
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$57 49.2% undervalued intrinsic discount
FcRn Autoimmune Therapies Will Transform Long Term Prospects Backed By Strong Capital Support
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$22 31.6% overvalued intrinsic discount
Future FcRn Safety Demands And Pricing Pressure Will Constrain Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future FcRn Safety Demands And Pricing Pressure Will Constrain Long Term Prospects
Catalysts About Immunovant Immunovant develops FcRn-targeting therapies, including IMVT-1402 and batoclimab, for autoimmune diseases such as Graves' disease and difficult to treat rheumatoid arthritis. What are the underlying business or industry changes driving this perspective?Read more
AN
US$22
31.6% overvalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
32.59kx
Price in 2029
US$0
FcRn Autoimmune Treatments Will Build Durable Long Term Potential For This Undervalued Biotech
Catalysts About Immunovant Immunovant develops FcRn-targeting antibodies aimed at treating autoimmune diseases by reducing pathogenic IgG antibodies. What are the underlying business or industry changes driving this perspective?Read more
AN
US$41.13
29.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
263.8x
Price in 2029
US$0
FcRn Autoimmune Therapies Will Transform Long Term Prospects Backed By Strong Capital Support
Catalysts About Immunovant Immunovant is a clinical stage biopharmaceutical company developing FcRn-targeting therapies for autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
US$57
49.2% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
307.93x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Future FcRn Safety Demands And Pricing Pressure Will Constrain Long Term Prospects
Fair Value: US$22 31.6% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FcRn Autoimmune Treatments Will Build Durable Long Term Potential For This Undervalued Biotech
Fair Value: US$41.13 29.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FcRn Autoimmune Therapies Will Transform Long Term Prospects Backed By Strong Capital Support
Fair Value: US$57 49.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Immunovant, Inc. Key Details
About IMVT
- Founded
- 2018
- Employees
- 362
- CEO
- WebsiteView website
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
